Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-old male, who developed VOD with capillary leakage (CL) after allogeneic PBSCT. The patient presented with a maximum serum bilirubin of 25.4 mg/dl, weight gain (10% of baseline weight), generalized edema, cardiovascular insufficiency, complement activation, jaundice and a decreased AT and protein C functional activity. After VOD and CL were diagnosed the patient was treated with recombinant human plasminogen activator (rt-PA) and C1 esterase-inhibitor concentrate (C1-INH-C). The clinical symptoms resolved and the patient's status stabilized. The patient was in an adequate clinical state 5 months after transplantation. We noted that the combined therapy with rt-PA and C1-INH-C in this high-risk situation led to a resolution of VOD with CL. Keywords: veno-occlusive disease; capillary leakage; rt-PA; C1 esterase inhibitor Hepatic VOD is a complication after peripheral blood stem cell transplantation which presents with different degrees of severity. Liver damage caused by obliteration of the hepatic venules by fibrin material and sinusoidal congestion is suggested as the pathophysiological cause.
Hepatic VOD is a complication after peripheral blood stem cell transplantation which presents with different degrees of severity. Liver damage caused by obliteration of the hepatic venules by fibrin material and sinusoidal congestion is suggested as the pathophysiological cause.
1,2 Therefore the usual therapy for severe VOD is based on the principle of anticoagulation with heparin, recombinant plasminogen activator (rt-PA) and antithrombin (AT) substitution. 2, 3 A condition of vascular hyperpermeability classified as systemic capillary leak syndrome (CLS) is known as associated with or isolated from VOD. 1, 4 Hypovolemic shock and organ dysfunction are the clinical consequences of a fluid and protein shift from the intravascular to the inter- stitial space. 4 CLS is considered to be a systemic, inflammatory reaction. An activation of the complement system via the classical pathway has been described in CLS after interleukin-2 therapy as well as after BMT. 5, 8 Because the above mentioned treatment of VOD does not address the problem of complement activation, further to rt-PA, our patient received C1 esterase inhibitor (C1-INH-C) as the main physiological inhibitor of the classical pathway of the complement system. 5 VOD is divided into mild, moderate and severe forms with respect to severity of jaundice, weight gain, edema and ascites. 6 The severe form, as characterized by a maximum total bilirubin of 25 mg/dl, is associated with capillary leakage and a high incidence of multiple organ failure. 6 Whereas VOD in general is associated with a mortality of 45-48%, the mortality with severe VOD is reported to be as high as 98%. 1, 6 We present a patient with severe VOD and associated CL after PBSCT, who showed rapid resolution of clinical symptoms after treatment with rt-PA and C1-INH concentrate (C1-INH-C).
Case report
A 17-year-old male patient with acute lymphoblastic leukemia (pre-B-ALL) in second remission was referred to the BMT unit of the Department of Pediatric Hematology and Oncology, University of Düsseldorf, for PBSCT.
The preparative regimen prior to PBSCT included hyperfractionated total body irradiation (total dose 12 Gy) combined with 1 × 40 mg/kg body weight (BW) etoposide and 2 × 60 mg/kg BW cyclophosphamide.
Allogeneic-related stem cells were obtained from the HLA-compatible mother. The nucleated cell dose was 9.1 × 10 8 /kg BW (CD34 + cells 6.55 × 10 6 /kg BW). Graftversus-host disease (GVHD) prophylaxis consisted of CsA started 1 day before, and intravenous methotrexate (MTX) 15 mg/m 2 body surface 1 day after PBSCT. The patient received 50 U/kg BW heparin by continuous infusion for thrombosis prophylaxis.
Engraftment was documented 20 days after transplantation.
Clinical/laboratory findings and treatment
VOD was diagnosed on the basis of increasing jaundice (bilirubin Ͼ2 mg/dl), hepatomegaly and weight gain of 6-7% on day 6 after PBSCT. 1, 7 Ascites, another criterion of VOD, was not seen. Jaundice continued to increase after diagnosis and the patient complained of upper right abdominal pain with a liver palpable 5 cm below the costal margin.
An ultrasound investigation on day +13 confirmed an increased liver size of 19 cm in the anterior axillary line, an increase of 5 cm over the baseline value. Pleural or pericardial effusion and ascites were not seen. Also, flow in the hepatic veins was normal.
VOD became more severe with an associated CL on day +13. The patient developed generalized edema and cardiovascular insufficiency with a mean arterial pressure of 43-51 mmHg. The patient was tachycardic with a heart rate of 130-145/min. A weight gain of 8% over baseline was seen.
Also, bilirubin levels increased significantly after day +12 (Figure 1a ). The value was 13.4 mg/dl on day +13 and reached a maximum level of 25.4 mg/dl on day +17 with a direct bilirubin ranging from 11.2 to 21.0 mg/dl.
Because of the severe VOD, informed consent was taken for therapy. The patient was treated with rt-PA for 4 days between days +13 and +16. The starting dose was 1 × 0.4 mg/kg BW and 1 × 0.8 mg/kg BW were administrated on the following 3 days (Figure 1b) . Heparin was continued with 50 U/kg BW except on days +14 and +15, when the patient received 100 U/kg BW heparin.
Cardiovascular function stabilized on day +13 after the first dose of rt-PA and 1000 ml human albumin 5%.
On day +14 the weight gain exceeded 10% over baseline (no difference in total fluid intake) and did not respond to diuretics (6.5 mg/kg × day furosemide).
Because of complement activation, as confirmed by increasing C5a levels from 0.94 g/l on day +13 to 2.5 g/l on day +14, C1-INH-C therapy started on day +14 (C1-INH levels were not measured). C1-INH-C was given at an initial dose of 60 U/kg BW followed by 8 × 30 U/kg BW and 3 × 15 U/kg BW C1-INH-C every 12 h until day +19. After two doses of C1-INH-C we observed a negative fluid balance of 530 ml over 24 h, mean blood pressures between 65 and 80 mmHg and a heart rate of 120-130/min.
Although AT was substituted from day +11 to +19 with 20-30 U/kg BW, the values for AT decreased from 115% baseline level to a minimum of 82% on day +14. The values for protein C were also low with a minimum level of 20% on day +14 (Figure 1c) .
With combined therapy with rt-PA and C1-INH-C the clinical and laboratory findings improved slowly until day +18. The patient's body weight returned to baseline on day +18, and bilirubin values decreased after day +17 reaching normal values (Ͻ2 mg/dl) on day +40. The AT level (106%) returned to normal on day +16, the C5a level (0.94 g/l) on day +19 and the protein C level (76%) on day +21.
Figures 1a-c show the parameters of VOD and CL from the onset of the complications to the clinical resolution.
The patient was in an adequate clinical status 5 months after transplantation. Liver parameters including bilirubin showed normal values. 
Discussion
VOD is a known complication after bone marrow transplantation. However, the underlying pathophysiological mechanisms are not fully understood which is why there is no well established treatment regimen. 1, 3, 7 Low-dose heparin, prostaglandin E, pentoxifylline, AT substitution andprobably most promisingly -rt-PA therapy have been used to date.
2,3
The rationale of rt-PA therapy is based on its fibrinolytic activity, which is supposed to unblock the hepatic postsinusoidal obstruction -a major finding in VOD. 1, 7 The role of AT substitution still remains unclear, although clinical improvement was seen and the risk of unwanted bleeding might be avoidable by AT substitution. 2 CLS is another severe complication after bone marrow transplantation itself and also occurs in connection with VOD.
In this report one patient with the clinical diagnosis of VOD and associated CL was treated with rt-PA and continuous AT substitution. The increased AT consumption in this patient might be due to hepatic dysfunction rather than being related to DIC. Regarding the pathophysiology of CLS, we measured the C5a level as a significant parameter for complement activation in these patients. 8 Because the VOD treatment (anticoagulants) does not influence the associated vascular hyperpermeability, we intended to inhibit complement activation by C1-INH-C. 4, 8 C5a levels decreased from 2.4 g/l on day +14 to 0.94 g/l on day +19. We observed clinical resolution of the symptoms as decreased weight to baseline, improved jaundice and cardiovascular function during therapy with rt-PA and C1-INH-C. Although thrombolytic therapy is potentially hazardous in BMT patients with thrombocytopenia, 9 no significant hemorrhage was observed in our patient or in other cases. 2, 3 To date, there is little experience with C1-INH-C treatment in VOD patients. We suggest that C1-INH-C is a rationale therapy in patients with severe VOD developing CL with classical complement activation. The rt-PA treatment seemed to have the postulated effect of unblocking the hepatic obstruction, because our patient showed clinical improvement in terms of liver function, even though no inverse blood flow in the hepatic veins had ever been observed.
A few case reports of moderate VOD (maximum bilirubin of 10 mg/dl) without CL have described adequate treatment with rt-PA and continuous AT substitution. 2, 3, 7 We assume, that this regimen would have been effective for VOD in our patient, but would not have addressed the symptoms of associated CL. Refering to the high morbidity and mortality associated with severe VOD, 1, 6 C1-INH-C seems to improve the treatment and outcome of severe VOD when given with rt-PA and AT treatment.
In conclusion, we suggest, that rt-PA and C1-INH-C could be used as combined treatment in patients with severe VOD and associated capillary leakage. We found an inhibition of the classical pathway of the complement activation resulting in a resolution of clinical symptoms. Controlled multicenter trials of this treatment regimen should stratify the clinical criteria of VOD for diagnosis, treatment and outcome.
